Long-acting cabotegravir and rilpivirine (CAB/RPV) administered intramuscularly monthly or every 2 months yielded high rates of efficacy and a favorable safety profile in women with HIV, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results